정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 331 | Completed | Study to Evaluate the Safety and Efficacy of ATYR1923 In Patients With Severe Pneumonia Related to COVID-19 | SARS-CoV-2 (COVID-19) Severe Pneumonia | Drug: ATYR1923 1 mg/kg Drug: ATYR1923 3 mg/kg Drug: Placebo |
Phase 2 | aTyr Pharma, Inc. | INDUSTRY | 32 | All | 18 Years ~ 75 Years | University of Alabama at Birmingham, Birmingham, Alabama, United States aTyr Investigative Site, Washington, District of Columbia, United States University of Miami, Miami, Florida, United States University of Iowa, Iowa City, Iowa, United States Anne Arundel Medical Center, Annapolis, Maryland, United States aTyr Investigative Site, Vineland, New Jersey, United States aTyr Investigative Site, Toledo, Ohio, United States Inova Fairfax Medical Campus, Falls Church, Virginia, United States Alliance Medical Service, Cardio Pulmonary Research, Guaynabo, Puerto Rico Manati Medical Center, Manati, Puerto Rico |
| 330 | Completed | Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19) | COVID-19 | Biological: GAMUNEX-C Drug: Standard Medical Treatment |
Phase 2 | Grifols Therapeutics LLC | INDUSTRY | 100 | All | 18 Years | Chandler Regional Medical Center, Chandler, Arizona, United States Southern California Research Center, Coronado, California, United States University of Illinois at Chicago, Chicago, Illinois, United States Via Christi Research, Wichita, Kansas, United States University of Louisville, Louisville, Kentucky, United States Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States McLaren Flint, Flint, Michigan, United States McLaren Health Care-Macomb, Mount Clemens, Michigan, United States McLaren Health Care Oakland, Pontiac, Michigan, United States CHI Health, Omaha, Nebraska, United States Columbia University Medical Center, New York, New York, United States Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States Summa Health, Akron, Ohio, United States Temple University Hospital, Philadelphia, Pennsylvania, United States Allegheny Health Network Research Institute, Pittsburgh, Pennsylvania, United States CHRISTUS Health, Tyler, Texas, United States MultiCare Deaconess Hospital, Spokane, Washington, United States MultiCare Tacoma General Hospital, Tacoma, Washington, United States |
| 329 | Completed | Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19) | COVID-19 | Biological: Intravenous Immune Globulin Drug: Standard Medical Treatment |
Phase 2 | Instituto Grifols, S.A. | INDUSTRY | 100 | All | 18 Years | Hospital Universitario Infanta Sofia, San Sebastian De Los Reyes, Madrid, Spain Hospital Germans Trias i Pujol, Badalona, Spain Hospital Del Mar, Barcelona, Spain Hospital Universitari Vall d'Hebron, Barcelona, Spain Hospital Universitari de Bellvitge, Barcelona, Spain Hospital de la Santa Creu i Sant Pau, Barcelona, Spain Hospital Universitario de Getafe, Getafe, Spain Hospital Arnau de Vilanova, Lleida, Spain Hospital General Universitario Gregorio Maranon, Madrid, Spain Hospital Clinico San Carlos, Madrid, Spain |
| 328 | Recruiting | Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19) | COVID-19 | Biological: Liquid Alpha1-Proteinase Inhibitor (Human) Drug: Placebo Drug: Standard Medical Treatment |
Phase 2 | Grifols Therapeutics LLC | INDUSTRY | 100 | All | 18 Years | Birmingham VA, Birmingham, Alabama, United States St. Joseph's Hospital, Phoenix, Arizona, United States University of Miami Hospital, Miami, Florida, United States Sparrow Hospital, Lansing, Michigan, United States Hannibal Clinic, Hannibal, Missouri, United States Kansas City VA, Kansas City, Missouri, United States CHI Health Center, Omaha, Nebraska, United States Columbia University Medical Center, New York, New York, United States Temple University Hospital, Philadelphia, Pennsylvania, United States Memphis VA, Memphis, Tennessee, United States University of Utah, Salt Lake City, Utah, United States MultiCare Tacoma General Hospital, Tacoma, Washington, United States AngioCor Blumenau, Blumenau, Santa Catarina, Brazil Hospital Sao Jose, Criciuma, Santa Catarina, Brazil Hospital das Clinicas da Faculdade de Medicina de Botucatu, Botucatu, Sao Paulo, Brazil Hospital Dia do Pulmao, Blumenau, Brazil Hospital Alemao Oswaldo Cruz, Sao Paulo, Brazil Universidade Federal de Sao Paulo, Sao Paulo, Brazil Hospital Padre Hurtado, Santiago, Chile Hospital Carlos Van Buren, Valparaiso, Chile Fundacion Oftalmologica de Santander, Bucaramanga, Santander, Colombia Unidad Medica para la Salud Integral, San Nicolas de los Garza, Mexico |
| 327 | Completed | Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19 | COVID-19 | Biological: Prolastin Drug: Standard Medical Treatment |
Phase 2 | Instituto Grifols, S.A. | INDUSTRY | 100 | All | 18 Years | Hospital Universitario de Burgos, Burgos, Castilla Leon, Spain Hospital Universitari Germans Trias i Pujol, Badalona, Spain Hospital Clinic de Barcelona, Barcelona, Spain Hospital Universitario Valle de Hebron, Barcelona, Spain Hospital Clinico San Carlos, Madrid, Spain Hospital General Gregorio Maranon, Madrid, Spain Hospital Universitario Infanta Leonor, Madrid, Spain Hospital Universitario Principe de Asturias, Madrid, Spain Hospital Universitario Ramon y Cajal, Madrid, Spain |
| 326 | Withdrawn | Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19 | COVID19 | Drug: 50 mg/mL Virazole Drug: 100 mg/mL Virazole |
Phase 1 | Bausch Health Americas, Inc. | INDUSTRY | 0 | All | 18 Years | |
| 325 | Completed | Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19 | COVID19 | Drug: 50 mg/mL Virazole Drug: 100 mg/mL Virazole |
Phase 1 | Bausch Health Americas, Inc. | INDUSTRY | 51 | All | 18 Years | Bausch Health Site 201, Athens, Attika, Greece Bausch Health Site 203, Athens, Attika, Greece Bausch Health Site 204, Alexandroupoli, Evros, Greece Bausch Site 304, Tijuana, Zona Rio, Mexico |
